AstraZeneca plc (AZN) Receives Consensus Recommendation of “Hold” from Analysts

AstraZeneca plc (LON:AZN) has been assigned a consensus rating of “Hold” from the twenty-three analysts that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 5,641.31 ($73.48).

AZN has been the subject of a number of research reports. Barclays restated an “overweight” rating and set a GBX 6,600 ($85.97) target price (up from GBX 6,500 ($84.67)) on shares of AstraZeneca in a report on Friday, August 10th. Deutsche Bank restated a “buy” rating and set a GBX 6,000 ($78.16) target price (up from GBX 5,700 ($74.25)) on shares of AstraZeneca in a report on Friday, July 13th. Credit Suisse Group set a GBX 5,900 ($76.85) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, July 27th. JPMorgan Chase & Co. set a GBX 5,800 ($75.55) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, July 20th. Finally, Liberum Capital restated a “hold” rating on shares of AstraZeneca in a report on Friday, August 31st.

Shares of AstraZeneca stock traded down GBX 18 ($0.23) on Wednesday, hitting GBX 5,652 ($73.62). The company had a trading volume of 912,842 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52 week low of GBX 4,260 ($55.49) and a 52 week high of GBX 5,520 ($71.90).

The business also recently announced a dividend, which was paid on Monday, September 10th. Shareholders of record on Thursday, August 9th were given a GBX 68.40 ($0.89) dividend. The ex-dividend date was Thursday, August 9th. This represents a yield of 1.19%.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Diversification For Individual Investors

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply